Cytogenetic abnormalities and early response to treatment are the main prognostic factors in acute myeloid leukemia (AML). Recently, NUP98/NSD1 (t(5; 11)(q35; p15)), a cytogenetically cryptic fusion, was described as recurrent event in AML, characterized by dismal prognosis and HOXA/B gene overexpression. Using split-signal fluorescence in situ hybridization, other NUP98-rearranged pediatric AML cases were identified, including several acute megakaryoblastic leukemia (AMKL) cases with a cytogenetically cryptic fusion of NUP98 to JARID1A (t(11;15)(p15;q35)). In this study we screened 105 pediatric AMKL cases to analyze the frequency of NUP98/JARID1A and other recurrent genetic abnormalities. NUP98/JARID1A was identified in 11/105 patients (10.5%). Other abnormalities consisted of RBM15/MKL1 (n ¼ 16), CBFA2T3/GLIS2 (n ¼ 13) and MLL-rearrangements (n ¼ 13). Comparing NUP98/ JARID1A-positive patients with other pediatric AMKL patients, no significant differences in sex, age and white blood cell count were found. NUP98/JARID1A was not an independent prognostic factor for 5-year overall (probability of overall survival (pOS)) or eventfree survival (probability of event-free survival (pEFS)), although the 5-year pOS for the entire AMKL cohort was poor (42±6%). Cases with RBM15/MLK1 fared significantly better in terms of pOS and pEFS, although this was not independent from other risk factors in multivariate analysis. NUP98/JARID1A cases were characterized by HOXA/B gene overexpression, which is a potential druggable pathway. In conclusion, NUP98/JARID1A is a novel recurrent genetic abnormality in pediatric AMKL.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by recurrent genetic aberrations. [1] [2] [3] At present, survival rates in pediatric AML are approximately 60-70%. 4, 5 The most important factors predicting clinical outcome are genetic and molecular aberrations, and early response to treatment. It is hypothesized that AML results from at least two different types of mutations, which non-randomly collaborate in leukemogenesis. 6 The type-I aberrations confer a proliferative or survival advantage, and consist for instance of mutations in tyrosine kinases, such as FLT3 or RAS mutations. Type-II mutations lead to impairment of the hematopoietic differentiation, and frequently consist of translocations, such as 11q23/MLL-rearrangements, AML1/ETO or CBFB/MYH11. 1, 6 Genome-wide studies have revealed many novel single-gene mutations. 7, 8 Recently, we described a cytogenetically cryptic translocation fusing nucleoporin 98 (NUP98), located on chromosome 11p15, to nuclear receptor binding SET domain protein 1 (NSD1), located on chromosome 5q35, as a recurrent event in cytogenetically normal AML (CN-AML). 9, 10 In children with CN-AML, the frequency was 16.1%, whereas in adult CN-AML, the frequency was 2.3%. 9, 11 AML patients with NUP98/NSD1-translocated leukemia had a dismal prognosis. 9 Of interest, NUP98/ NSD1-rearranged cases were associated with overexpression of HOXAB genes, suggesting an oncogenic mechanism similar to AML cases characterized by MLL-rearrangements or NPM1 gene mutations. 9, 12 Searching for other NUP98-driven leukemias, we screened a large cohort using split-signal fluorescence in situ hybridization (FISH) to detect other NUP98 breaks, as NUP98 is known to have many different partner genes. 10 In one patient, another fusion partner was identified, that is, JARID1A, which was previously described by van Zutven et al. 13 in a single case from our institute. This case was classified as acute megakaryoblastic leukemia (AMKL), which can either occur de novo or in the context of Down syndrome-associated myeloid leukemia with mutations in GATA1. Non-Down syndrome AMKL is characterized by a limited number of specific genetic abnormalities, including the t(1;22)(p13;q13) translocation fusing RBM15 to MKL1, formerly known as OTT/MAL.
14 In addition, recently Gruber et al. 15 described an inversion of chromosome 16, resulting in CBFA2T3/GLIS2 gene fusion as a repetitive event in AMKL, with an overall frequency of 27%. This frequency was confirmed by Thiollier et al. 16 In this study, we show that NUP98/JARID1A is a novel recurrent cryptic translocation in pediatric AMKL. In addition, we characterized the genetic abnormalities of a larger series of pediatric AMKL patients, including the RBM15/MKL1 translocation and the recently identified fusion of CBFA2T3 to GLIS2, and investigated the prognostic significance of these aberrations.
MATERIALS AND METHODS

Patient samples
The cohort of newly diagnosed pediatric AML patients with available peripheral blood or bone marrow samples taken at initial diagnosis included in this study was previously described by Hollink et al. 9 (n ¼ 293; age, 0-18 years). Samples were provided by the Dutch Childhood Oncology Group (The Hague, The Netherlands; n ¼ 141), the AMLBerliner-Frankfurt-Mü nster (BFM) Study Group (Germany and Czech Republic; n ¼ 128) and the Saint Louis Hospital (Paris, France; n ¼ 24) (Supplementary Table 1) . 9 Morphological classification and karyotyping were centrally reviewed by each study group. Cytogenetic aberrations in this group were distributed representatively for the frequencies seen in pediatric AML. 17, 18 Based on the identification of NUP98/JARID1A in AMKL patients, 105 additional samples of newly diagnosed pediatric non-Down syndrome AMKL patients were obtained. These were kindly provided by the aforementioned study groups (n ¼ 45), and the North-American Children's Oncology Group (Arcadia, CA, USA; n ¼ 60). In total, 33 samples consisting of viable frozen bone marrow or peripheral blood were available, as well as 72 samples, of which only RNA or cDNA was available.
To investigate the presence of NUP98/JARID1A in Down syndrome AMKL patients, a series (n ¼ 16) was provided by the Dutch Childhood Oncology Group and the AML-BFM Study Group.
After thawing the samples, leukemic cells were purified as previously described. 19 Blast percentages were assessed morphologically using cytospins stained with a May-Grü nwald Giemsa staining. Isolation of genomic DNA and total cellular RNA from the samples was performed using Trizol reagent. All patients were treated with intensive collaborative group cytarabine-anthracycline-based pediatric AML-treatment protocols. Each collaborative study group provided us with centrally reviewed morphological and cytogenetic classification and clinical follow-up data of the AMKL patient cohort.
Institutional review board approval for these studies had been obtained in the participating centers.
Split-signal FISH for NUP98
For detection of NUP98 rearrangements, FISH experiments were performed on newly diagnosed pediatric AML cases, excluding cases where the driving oncogenic type-II abnormality was already known, such as PML/RARA or MLL rearrangements. Dual-color FISH analysis for detection of NUP98 breaks was performed on thawed cytospin slides using the 44-kb overlapping bacterial artificial chromosome probes RP11-120E20 and RP11-348A20 (BACPAC Resources Center, Oakland, CA, USA), as described previously. 20 Detection of the NUP98/JARID1A transcript The presence of NUP98/JARID1A and the reciprocal JARID1A/NUP98 were determined by reverse-transcriptase PCR (RT-PCR) (Supplementary Table 2a ). Purified PCR products were directly sequenced on a PRISM 3100 genetic analyzer (Applied Biosystems, Foster City, CA, USA) and analyzed using CLCWorkbench (Version 3.5.1; CLC Bio, Aarhus, Denmark).
Cytogenetic and molecular characterization
Samples were screened for cytogenetic aberrations using standard chromosome banding analysis at initial diagnosis by the collaborative study groups. All cases with unknown karyotype were screened for MLLrearrangements, and those with a reported MLL-rearrangement were confirmed, using split-signal FISH for MLL. In case of a positive split signal as seen with FISH, partner gene identification was performed with translocation partner-specific PCR for the following translocations: MLL/AF6 (also known as MLL/MLLT4), MLL/AF9 (also known as MLL/MLLT3), MLL/AF10 (also known as MLL/MLLT10), MLL/ENL (also known as MLL/MLLT1) and MLL/ELL. 21 Fusions of RBM15/MKL1 and CBFA2T3/GLIS2 were detected using conventional karyotyping, RT-PCR and sequencing.
To identify other aberrations, RT-PCR was performed on hotspot areas of the following genes: NRAS, KRAS, NPM1, MLL-PTD, CEBPA, FLT3, PTPN11, KIT and WT1 as previously described by Balgobind et al. 1 Primers and probes used for analyzing these molecular aberrations are shown in Supplementary Table 2a. Gene-expression profiling Gene-expression profiling (GEP) data of 274/293 pediatric AML patients, of which 8 were classified as AMKL cases, were available from earlier studies. 22 Checking RNA integrity, processing the Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA) and normalizing and analyses of the data were performed as described previously. 9 Original data are available in the Gene Expression Omnibus repository (http://www.ncbi.nlm.nih.gov/geo; accession GSE17855).
Taqman validation of HOX gene-expression levels GEP data were only available for a limited number of patients with AMKL, hence we performed specific real-time quantitative PCR (RT-qPCR) for various HOXA and HOXB genes to study HOX gene expression in AMKL patients. Results obtained with GEP were validated with RT-qPCR in a series of pediatric AML cases, and, in addition, pediatric AMKL cases were studied with RT-qPCR. RT-qPCR was performed in duplicate in cases with at least 70% blasts. Primer and probe sets are shown in Supplementary Table 2b . The average cycle threshold value was used to determine the expression levels of the different HOX genes in comparison with the expression levels of the reference gene GAPDH, using the comparative cycle time method. Correlation between GEP data and RT-qPCR was examined.
Statistical analysis
Statistical analyses were performed with SPSS 17.0 (SPSS, Chicago, IL, USA). Correlation coefficients were measured using Spearman's correlation. Categorical variables were compared using the w 2 -test or Fisher's exact test, and continuous variables using Mann-Whitney U-test. To assess outcome, the following parameters were used: complete remission, defined as o5% blasts in the bone marrow, with regeneration of trilineage hematopoiesis, plus absence of leukemic cells in the cerebrospinal fluid or elsewhere, probability of event-free survival (pEFS), defined as the time between diagnosis and first event including non-responders (calculated as an event on day 0), death of any cause and second malignancies, and probability of overall survival (pOS), defined as the time between diagnosis and death. Both pEFS and pOS were estimated by the Kaplan-Meier method, and groups were compared with the log-rank test. The cumulative incidence of non-response or relapse (pCIR), defined as time between diagnosis and relapse and with nonresponders included as an event on day 0, was analyzed by the Kalbfleisch and Prentice method, and groups were compared with the Gray's test. Multivariate Cox regression analysis was used to determine the independency of prognostic markers. Statistical significance was considered if P-values were o0.05.
RESULTS
Identification of the NUP98/JARID1A fusion Of 293 well-characterized pediatric AML cases, 122 patients with available material, and in which the driving oncogenic type-II abnormality had not been identified, were analyzed with splitsignal FISH for NUP98 abnormalities. In 26 patients, a split signal was detected, suggesting a break in the NUP98 gene. Using a candidate gene approach to identify potential cytogenetically cryptic fusion partners, we identified JARID1A to be fused to NUP98. Subsequently, the entire cohort (n ¼ 293) was screened for presence of the NUP98/JARID1A fusion, which revealed three additional cases, of whom no material for FISH was available. In all patients, the fusion was cryptic. Three out of four NUP98/JARID1A-positive cases were morphologically diagnosed with AMKL (FAB M7). One patient was classified as an acute monoblastic leukemia (FAB M5), and this patient was the only NUP98/JARID1A-positive case out of 65 (1.5%) acute monoblastic leukemia patients (Supplementary Table 1 ).
NUP98 aberrations in AMKL To identify the frequency of NUP98/JARID1A in de novo AMKL, we screened an extended pediatric AMKL cohort of 105 de novo non-Down syndrome samples using RT-PCR. The NUP98/JARID1A fusion was detected in 11 out of 105 (10.5%) AMKL patients and was confirmed with direct sequencing. Sequence analysis showed an identical in-frame fusion of exon 13 of NUP98 to exon 27 of JARID1A in 10 cases (Figure 1 ). In one case, the breakpoint of NUP98 was detected in exon 14, and part of exon 14 of NUP98 was fused in-frame to exon 27 of JARID1A. The reciprocal product was found in two out of eight cases only, three cases could not be tested due to lack of material.
Split-signal FISH on NUP98 could be performed in 25 AMKL cases, and revealed four additional cases with a break in the NUP98 gene. In three patients, the fusion partner has not been identified yet. These patients were negative for NUP98 fusion to PHF23, NSD1, TOP1, DDX10 and JARID1A, with breakpoints previously described. 9, 23, 24 One patient carried the NUP98/NSD1 fusion. Among the 16 Down syndrome AMKL patients, no NUP98/ JARID1A fusions were found.
Extensive genetic characterization of the AMKL cohort We further investigated the 105 pediatric AMKL cases for various type-II abnormalities, as depicted in Figure 2 . The classical t(1;22)(p13;q13) fusing RBM15 to MKL1 was found in 16 out of 105 patients (15.2%). In 13 out of 105 cases, we found the recently reported CBFA2T3/GLIS2 fusion, as described by Gruber et al.
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MLL-rearrangements were identified in 10/96 cases with available material, that is,
and MLL/ENL (n ¼ 1). In addition, three MLL-PTD cases were identified. Other translocations consisted of one case with t(16;21)(p11;q22), resulting in the FUS/ERG fusion gene, and a t(7;12)(q36;p13), resulting in a fusion of HLXB9 with ETV6 in another patient. All aberrations were mutually exclusive.
In 39% of the AMKL cases, currently no type-II aberration could be detected using RT-PCR or FISH screening for the abnormalities mentioned above. However, cytogenetic data did reveal various complex and other random aberrations in 36 cases.
Forty-five out of 105 patients had material available for type-I mutation screening. Only 3 out of these 45 patients harbored a type-I mutation in one of the screened hotspot areas. All three consisted of a RAS mutation (Table 1a) . No other mutations were found.
Characteristics of genetically distinct groups of pediatric AMKL When we compared the clinical characteristics of the children with AMKL included in this study versus a population-based AMKL cohort included in the AML-BFM 93/98 studies, no significant differences in sex (P ¼ 0.88), age (P ¼ 1.0) or white blood cell count (P ¼ 1.0) were seen. Concerning clinical outcome, there were no significant differences in event-free (P ¼ 0.44) or overall survival (P ¼ 0.56), nor in the cumulative incidence of relapse (P ¼ 0.93).
The median age at diagnosis of the 105 pediatric AMKL cases was 1.5 years (0.1-15.4 years). NUP98/JARID1A-positive cases (Table 1b) did not differ significantly from the other pediatric AMKL cases, concerning age at diagnosis (median age 1.8 years, range 0.9-4.9 years) compared with 1.5 years (range 0.1-15.1 years), respectively (P ¼ 0.169); nor in sex (55% versus 53% female, respectively); nor in white blood cell count at diagnosis (11.8 Â 10 9 /l versus 16.0 Â 10 9 /l median, respectively, P ¼ 0.141 ,  Table 1a ). Also, in patients with the CBFA2T3/GLIS2 fusion (n ¼ 13, Table 3a) were significantly younger in comparison with all other AMKL cases (median 0.5 versus 1.6 years, Po0.01), but sex and white blood cell count at diagnosis did not differ significantly (Table 1a) . Moreover, the MLL-rearranged AMKL cases (Supplementary Table 3b ) did not differ significantly from the other AMKL cases for the aforementioned clinical characteristics (Table 1a) .
HOX gene expression Principal component analysis based on HOXA and HOXB gene expression in the 274 patients with available gene-expression profiles, as we reported previously, showed that AML can be subdivided into three clusters based on HOXA and HOXB expression. 9 All four NUP98/JARID1A-fused patients, of whom GEP data were available, were categorized in the cluster with overexpression of both HOXA and HOXB genes, together with the NUP98/NSD1-rearranged cases, DEK/NUP214-rearranged cases and the NPM1 gene-mutated cases (Figure 3a ).
Strong correlations (r ¼ 0.6192-0.9184, Po0.05) between GEP data and RT-qPCR were found for HOXA5, -A7, -A9, -A10, -B2, -B4, -B5 and -B6 (n ¼ 40, selection of well-characterized representative pediatric AML cases, Supplementary Figure 1) .
We further studied HOXA and HOXB expression with RT-qPCR in 36 AMKL cases, of which six were positive for NUP98/JARID1A. The other 30 cases consisted of other NUP98 rearrangements (n ¼ 4), CBFA2T3/GLIS2 (n ¼ 7), MLL rearrangements (n ¼ 4), RBM15/MKL1 Figure 1 . Sequence analysis of a NUP98/JARID1A-positive case. RT-PCR analysis using NUP98-and JARID1A-specific primers revealed a NUP98/ JARID1A fusion. Sequence analysis confirmed an in-frame fusion between NUP98 exon 13 and JARID1A exon 27. The in-frame fusion was identical in 10 out of 11 cases. (n ¼ 1), MLL-PTD (n ¼ 1), t(7;12) (n ¼ 1) and 12 cases with unidentified type-II aberration. Significantly, higher expression levels of HOXA5, -A9, -A10, -B2, -B3, -B4, -B5 and -B6 were found in the NUP98/JARID1A-fused patients in comparison with the other pediatric AMKL patients (Po0.01) (Figure 3b) . Of interest, CBFA2T3/GLIS2-and RBM15/MKL1-translocated patients did not have aberrant HOX gene expression. In the MLL-rearranged patients, as expected, we could confirm higher HOXA5, -A7, -A9 and -A10 expression, but not HOXB overexpression, in comparison with other AMKL patients.
Prognostic relevance of NUP98/JARID1A and other genetic subgroups in AMKL Follow-up data for survival analysis was available in 73 cases. Follow-up data were not available for the AAML00531 study of the Children's Oncology Group. Patient characteristics did not differ between the total cohort (n ¼ 105) and the cases used for prognostic markers (n ¼ 73), and was comparable to other studies earlier described. 25 Overall, 5-year pOS in pediatric AMKL was 42 ± 6%, and pEFS was 34 ± 6%. The pOS, pEFS and pCIR of the included cohort did not show significant differences compared with the pediatric non-Down syndrome AMKL patients included in the BFM 93/98 protocols (P ¼ 0.56, P ¼ 0.44 and P ¼ 0.93, respectively, Supplementary Figure 2) .
The complete remission rate of NUP98/JARID1A-positive cases was 78%, similar to the negative cases (78%). The 5-year pEFS was 22±14% in NUP98/JARID1A-positive cases (n ¼ 9), and 36±6% in the negative cases (P ¼ 0.54). Although the 5-year pOS of NUP98/ JARID1A-positive cases was 22 ± 14% compared with 45 ± 7% for NUP98/JARID1A-negative cases, this difference was not statistically significant (P ¼ 0.22). In addition, there was no significant difference in pCIR; 56 ± 19% in NUP98/JARID1A-positive versus 54±7% in NUP98/JARID1A-negative cases (P ¼ 0.94, Figure 4) . Out of the nine patients positive for NUP98/JARID1A, two were non-responders, three died after relapse and two patients died in complete remission due to treatment-related mortality. Cases with a positive split-signal FISH on NUP98 or other NUP98 aberrations did not differ significantly from other cases with respect to pOS, pEFS and pCIR.
In CBFA2T3/GLIS2-positive patients (n ¼ 8), the 5-year pEFS, pOS and pCIR did not differ significantly from all other AMKL cases; pEFS was 19 ± 16% in positive cases and 35 ± 6% in negative cases (P ¼ 0.66), 5-year pOS was 35 ± 20% in positive cases compared with 42 ± 6% in negative cases (P ¼ 0.52), and pCIR was 81 ± 21% versus 51±7% at 5 years, respectively (P ¼ 0.21, Figure 4) . 
Abbreviations: CN-AML, cytogenetically normal acute myeloid leukemia; MLL, mixed-lineage leukemia; n, number of cases; WBC, white blood cell count; y, years. a Significant younger age at diagnosis in RBM15/MKL1-positive patients versus others (Po0.01). The 5-year pOS was significantly better for RBM15/MKL1-positive patients (n ¼ 11, 82±12% versus 36±6% in negative cases, P ¼ 0.043), and 5-year pEFS was also significantly better with 73 ± 13% in the positive cases versus 27 ± 6% in other AMKL (P ¼ 0.039). This was mainly caused by a lower relapse rate, as pCIR was also significantly lower in this group (9±9% versus 62±7%, P ¼ 0.004, Figure 4 ).
As cases with RBM15/MKL1 are associated with younger age, we performed multivariate analysis for RBM15/MKL1, including age at diagnosis and white blood cell count as covariable. We found that RBM15/MKL1 was not an independent prognostic factor for pOS (hazard ratio (HR) 0.31 (95% confidence interval (CI) 0.07-1.36), P ¼ 0.12) or pEFS (HR 0.40 (95% CI 0.12-1.37), P ¼ 0.15), nor was age for pOS (HR 0.56 (95% CI 0.24-1.32), P ¼ 0.19), and pEFS (HR 0.65 (95% CI 0.30-1.41), P ¼ 0.28).
DISCUSSION
In this study, we identified fusion of NUP98 located on chromosome 11p15 to JARID1A located on chromosome 12p13 as a novel recurrent event in approximately 11% of patients with pediatric AMKL. The NUP98/JARID1A fusion is cryptic as NUP98 is located 3 Mb from the 11p telomere and JARID1A is located at the telomeric end of 12p13, and therefore undetectable with conventional karyotyping. This fusion gene was mutually exclusive with other type-II aberrations. This provides further evidence for the role of NUP98 abnormalities in pediatric AML, in addition to the 16% of pediatric CN-AML cases that harbor a NUP98/NSD1 fusion. 9 The frequency of the NUP98/JARID1A fusion in AMKL is comparable to the RBM15/MKL1 fusion (14% in our series), which is a well-known aberration in AMKL, and also comparable to the frequency of the recently described CBFA2T3/GLIS2 fusion. 16 In our series, the CBFA2T3/GLIS2 fusion was detected in 12% of the AMKL cases, which is lower than reported by Gruber et al. 15 (27%) and Thiollier et al. 16 (31%). The latter studies included less patients (n ¼ 35 and n ¼ 22, respectively), and extensive information about selection bias concerning age at diagnosis in these studies is not available.
Altogether, with the identification of NUP98/JARID1A specific non-random type-II abnormalities can now be defined in roughly 60% of pediatric AMKL cases. NUP98 breaks were seen in 3% of the cases, but the underlying aberration could not be identified.
Interestingly, the number of patients with a type-I aberration was very low (7%, n ¼ 45), as previously reported by Hama et al.
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According to the Kelly and Gilliland 6 hypothesis, collaborating type-I and -II aberrations are needed in order to develop full-blown leukemia. Recent evidence suggests that different types of NUP98 fusions are frequently associated with FLT3/ITD (56-91%) and WT1 (36-50%). 9, 27, 28 However, all AMKL patients were negative for WT1 and FLT3/ITD mutations, including the NUP98-rearranged cases. Therefore, the collaborating type-I events in AMKL remain to be elucidated.
Recently, we described NUP98/NSD1 as an independent variable for dismal outcome in pediatric AML, because of a high frequency of relapsed/refractory disease. 9 Although outcome of the NUP98/ JARID1A cases was poor, there was no significant difference compared with other AMKL cases. However, outcome in AMKL patients in general was poor with a 5-year survival rate of only 41%, and a high incidence of refractory disease or relapse, despite modern intensive therapy. Exceptions were patients with the RBM15/MKL1 fusion, which had a clearly better outcome with approximately 80% overall survival, which was due to a low relapse rate. However, this fusion transcript could not be confirmed as an independent prognostic factor, probably because of the number of patients.
By unraveling the driving oncogenic events, the potential for targeted therapy needs to be taken into account, which may ultimately increase survival rates. A prime example of the potential for targeted therapy in HOX-upregulated AML is the activity of DOT1L inhibitors in MLL-rearranged AML in vitro and in mouse models. 29 Similar to NUP98/NSD1-positive patients, in NPM1-mutated patients and patients with a DEK/NUP214 fusion, NUP98/JARID1A is associated with higher expression of several HOXA and HOXB genes, suggesting a common mechanism of leukemogenesis in these cases. This expression pattern is distinct from MLL-rearranged cases, which are characterized by overexpression of HOXA genes only. The leukemogenic role of activation of HOXB genes is, however, unknown to date. NUP98, like MLL, has many different partner genes. 10 Almost all fusion genes contain the NUP98 promoter and nearly all the NUP98 FG/GLFG repeats. These GLFG repeats result in recruitment of the coactivator CREBBP/p300, causing histone acetylation, resulting in transcriptional activation of different target genes, including several HOX genes as shown by the principal component analysis (Figure 2) . 6, 30, 31 This may suggest that specific histone acetyltransferase inhibitors may be potential candidate drugs in NUP98-rearranged leukemias.
JARID1A contains three plant homeodomain (PHD) fingers of which the C-terminal PHD finger is fused to NUP98 in the NUP98/JARID1A fusion. This is essential for leukemogenic transformation as demonstrated by Wang et al. 32 This PHD finger recognizes various histone 3 lysin 4 methylation states. 33 Fusion of NUP98 to this PHD finger of JARID1A leads to methylation of H3K4, which results in sustained upregulation of HOX genes and other transcription factors, maintaining a stem cell phenotype. 32, 34 This mechanism might function as second druggable target in NUP98/JARID1A-positive patients. In absence of available cell lines, we are currently generating a model to study this further.
As AMKL is rare and frequently associated with myelofibrosis, it is often difficult to obtain sufficient material for additional laboratory studies. Therefore, we had to obtain samples from various regions of Europe and North America. A potential drawback of that approach is that patients were treated on different protocols over a longer period of time. However, all protocols consisted of intensive chemotherapy using an anthracycline and cytarabine backbone, including stem cell transplantation in selected cases. Moreover, when comparing the clinical characteristics and outcome data of the patients presented in this paper versus a population-based cohort of the AML-BFM Study Group, no significant differences were found in those parameters, suggesting that our cohort was representative for pediatric AMKL.
In conclusion, we report NUP98/JARID1A as a novel recurrent cryptic translocation, which appears to be specific for pediatric AMKL. NUP98/JARID1A is associated with a high expression of HOXA and HOXB genes, indicative of a stem cell phenotype, similar to what we reported for NUP98/NSD1. With exception of the RBM15/MKL1-translocated patients, non-Down syndrome AMKL in general has a poor outcome, including the NUP98/ JARID1A cases.
Taken together, with the identification of the NUP98/JARID1A fusion, a type-II aberration can now be found in approximately 60% of pediatric AMKL cases.
